The George Washington University: I. JOB OVERVIEW Job Description Summary: Founded in 1824, the GW School of Medicine and Health Sciences (SMHS) is the 11th oldest medical school in... Washington, Washington DC

AbbVie: Company Description AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and addre... North Chicago, Illinois

Notice NOT-CA-24-061 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-062 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MD-24-009 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support research that includes education, outreach, and clinical access to improve the screening, diagnosis, and treatment of cancers among American Indians and Alaska Natives, particularly those living in rural communities.

Funding Opportunity PAR-24-239 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Specifically, this NOFO solicits R33 applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. This NOFO will support studies to assess the ability of the unique patterns of host biology (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with probiotic usage to detect the improvement of probiotic responsiveness. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or in human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage have been identified, as demonstrated with supportive preliminary data, but require further mechanistic studies to test for their causality or predictability. Applicants pursuing early-stage research to identify host biological patterns that may affect probiotic health outcomes should consider the companion (R61/R33) NOFO PAR-AT-24-XXX (TEMP-25412).

Funding Opportunity PAR-24-238 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with heterogeneity of probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33, will support studies to assess the ability of the unique patterns determined in the R61 phase to detect the improvement of probiotic responsiveness in rigorously designed mechanistic studies in relevant animal models or in human subjects. The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful completion of Transition Milestones that need to be clearly specified in the R61 phase application. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-AT-24-XXX (TEMP-25413).

Notice NOT-AG-24-025 from the NIH Guide for Grants and Contracts

Notice NOT-DC-24-034 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-145 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-068 from the NIH Guide for Grants and Contracts

Notice NOT-DE-25-029 from the NIH Guide for Grants and Contracts

Notice NOT-PM-24-004 from the NIH Guide for Grants and Contracts

Memorial Sloan Kettering Cancer Center: Pay Range: $55,439 - 100,940 Company Overview: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending... New York, New York

Memorial Sloan Kettering Cancer Center: Pay Range: $55,439 - 100,940 Company Overview: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending... New York, New York

InVitro Cell Research, LLC: We are hiring senior-level scientists with extensive experience in Translational Bioinformatics and Integrative Omics with a focus on using integra... Leonia, New Jersey

Shriners Children's: Company Overview: Shriners Children's is a family that respects, supports, and values each other. We are engaged in providing excellence in patient... Tampa, Florida

Regeneron Pharmaceuticals, Inc.: We are looking for a Lead IT Engineer who will support Laboratory Instrument Systems at our new Regeneron Cell Medicines (RCM) unit, located in the... Cambridge, Massachusetts

Memorial Sloan Kettering Cancer Center: Pay Range: $55,439 - 100,940 Company Overview: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending... New York, New York

Memorial Sloan Kettering Cancer Center: Pay Range: $55,439 - 100,940 Company Overview: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending... New York, New York